Selumetinib suppliers
Selumetinib
- CAS:
- 606143-52-6
- MF:
- C17H15BrClFN4O3
- MW:
- 457.68
Suppliers by country/region
Company Type
Properties
- Melting point:
- >219°C (dec.)
- Density
- 1.69
- storage temp.
- -20°
- solubility
- Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 2 mg/ml)
- pka
- 14.20±0.10(Predicted)
- form
- Beige powder.
- color
- White
- Stability:
- Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 2 months.
- InChI
- InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
- InChIKey
- CYOHGALHFOKKQC-UHFFFAOYSA-N
- SMILES
- C1N(C)C2=CC(C(NOCCO)=O)=C(NC3=CC=C(Br)C=C3Cl)C(F)=C2N=1
Safety Information
- Symbol(GHS)



GHS05,GHS07,GHS08
- Signal word
- Danger
- Hazard statements
- H317-H318-H361d-H373
- Precautionary statements
- P262-P280-P312
- target organs
- Gastrointestinal tract,Eyes,Urinary tract
- WGK Germany
- WGK 2
- HS Code
- 29349990
- Storage Class
- 11 - Combustible Solids
- Hazard Classifications
- Acute Tox. 4 Oral
Aquatic Chronic 4
Repr. 2
Skin Sens. 1
STOT RE 2
Use
In phase II clinical trials of radioiodine-refractory papillary thyroid carcinoma, 39 patients took daily oral doses of Selumetinib (100mg bid) for 28 days; results showed that 21 patients conditions stabilized (54%), 11 patients conditions worsened (28%), 49% patients conditions were stable for 16 weeks, 36% patients conditions were stable for 24 weeks, and survival terms did not progress to 32 weeks. Negative reactions mainly consisted of rashes (59%), diarrhea (44%), and weakness (41%). Some studies found that after treating 20 patients with thyroid cancer with Selumetinib (75mg bid) for 4 weeks, Selumetinib increased the iodine uptake and retention of patients with radioiodine-refractory papillary thyroid carcinoma. In a blind and random comparative study between a Selumetinib and Docetaxel (DOC) combination treatment group and DOC and placebo treatment group for 87 mutant NSCLSC patients, survival times were 9.4 months and 5.2 months, PFS were 5.3 months and 2.1 months, RR were 37% and 0%, thus showing dramatic differences. Selumetinibs main negative reactions include neutrophil depletion, dermatitis, and respiratory failure.
217 supplier list of "Selumetinib"
- Product Name:Selumetinib
- Products Intro:Purity: 98% | Package: 1KG
- Company Type: Trader
- Country/Region: CHINA
- Main Products: 5-Heptylresorcinol,Methyl 2-heptyl-4,6-dihydroxybenzoate,Cannabinoids Precursors,2,4-dihydroxy-6-propyl-benzoic acid methyl ester,Benzoic acid, 2-hexyl-4,6-dihydroxy-, methyl ester
- Product Name:Selumetinib
- Products Intro:Purity: 0.99|Package: 1KG
- Company Type: Trader
- Country/Region: CHINA
- Main Products: Tirzepatide,Semaglutide,Retaglutide,pregabalin,tadalafil
$2.00
- Product Name:Selumetinib
- Products Intro:Purity: 99% | Package: 1kg;2USD
- Company Type: Reagent
- Country/Region: CHINA
- Main Products: Nicotinamide riboside chloride,Curcumin,L(+)-Ascorbic acid,L-Glutamine,Stevioside Basic information
$47.00-81.00
- Product Name:Selumetinib
- Products Intro:Purity: 99.46% | Package: 25mg;47USD|50mg;63USD|100mg;81USD | CustNote: REAGENT;FOR LABORATORY USE ONLY
- Company Type: Trader
- Country/Region: UNITED STATES
- Main Products: Compound Libraries,Noval Small Molecucles,Nature Compounds,Inhibitory Antibodies,Life science Kits
- Product Name:Selumetinib
- Products Intro:Purity: 99.9%|Package: 1g
- Company Type: Trader
- Country/Region: CHINA





